Follow
Galler Gunther R.
Galler Gunther R.
Chief Technology Officer, Genagon Therapeutics
Verified email at genagon.com
Title
Cited by
Cited by
Year
MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb
C Xiao, DP Calado, G Galler, TH Thai, HC Patterson, J Wang, N Rajewsky, ...
Cell 131 (1), 146-159, 2007
13002007
Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage
SB Koralov, SA Muljo, GR Galler, A Krek, T Chakraborty, C Kanellopoulou, ...
Cell 132 (5), 860-874, 2008
7132008
HIV-1 Nef mimics an integrin receptor signal that recruits the polycomb group protein Eed to the plasma membrane
V Witte, B Laffert, O Rosorius, P Lischka, K Blume, G Galler, A Stilper, ...
Molecular cell 13 (2), 179-190, 2004
1092004
The pre‐B‐cell receptor induces silencing of VpreB and λ5 transcription
MJ Parker, S Licence, L Erlandsson, GR Galler, L Chakalova, ...
The EMBO journal 24 (22), 3895-3905, 2005
912005
Surface μ heavy chain signals down-regulation of the V (D) J-recombinase machinery in the absence of surrogate light chain components
GR Galler, C Mundt, M Parker, R Pelanda, IL Mårtensson, TH Winkler
The Journal of experimental medicine 199 (11), 1523-1532, 2004
882004
CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models
LK Kristensen, C Fröhlich, C Christensen, MC Melander, TT Poulsen, ...
Theranostics 9 (26), 8221, 2019
672019
Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform
T Gjetting, M Gad, C Fröhlich, T Lindsted, MC Melander, VK Bhatia, ...
MAbs 11 (4), 666-680, 2019
252019
Simultaneous targeting of two distinct epitopes on MET effectively inhibits MET-and HGF-driven tumor growth by multiple mechanisms
MM Grandal, S Havrylov, TT Poulsen, K Koefoed, A Dahlman, GR Galler, ...
Molecular cancer therapeutics 16 (12), 2780-2791, 2017
232017
CD4 (+) and CD8a (+) PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models. Theranostics. 2019; 9: 8221–38
LK Kristensen, C Fröhlich, C Christensen, M Melander, T Poulsen, ...
DOI: https://doi. org/10.7150/thno 37513, 8221-8238, 0
6
Anti-PD-1 antibodies and compositions
G Galler, M Gad, K Koefoed, ID Horak, T Bouquin, M Kragh, M Pedersen
US Patent 11,034,765, 2021
52021
Anti-LAG-3 antibodies and compositions
MM Grandal, VK Bhatia, T Gjetting, C Fröhlich, GR Galler, M Kragh, ...
US Patent 11,390,676, 2022
32022
Anti-PD-1 antibodies and compositions
J Lantto, T Bouquin, K Koefoed, T Gjetting, VK Bhatia, M Gad, GR Galler, ...
US Patent 11,359,018, 2022
32022
Anti-lag-3 antibodies and compositions
MM Grandal, VK BHATIA, T Gjetting, C Fröhlich, GR GALLER, M Kragh, ...
22018
Anti-lag-3 antibodies and compositions
MM Grandal, VK Bhatia, T Gjetting, C Fröhlich, GR Galler, M Kragh, ...
US Patent 11,834,503, 2023
12023
Anti-tim-3 antibodies and compositions
T Lindsted, T Gjetting, GR Galler, M Gad, MM Grandal, K Koefoed, ...
US Patent App. 17/741,967, 2023
12023
Anti-TIM-3 antibodies and compositions
T Lindsted, T Gjetting, GR Galler, M Gad, MM Grandal, K Koefoed, ...
US Patent 11,390,674, 2022
12022
Anti-pd-1 antibodies and compositions
G Galler, M Gad, K Koefoed, ID Horak, T Bouquin, M Kragh, M Pedersen
US Patent App. 17/324,508, 2021
12021
Pre-B-cell Receptor Mediated Regulation of the V (D) J-recombination Machinery in Murine B-lymphopoiesis
GR Galler
12004
Anti-lag-3 antibodies and compositions
MM Grandal, VK Bhatia, T Gjetting, C Fröhlich, GR Galler, M Kragh, ...
US Patent App. 18/490,500, 2024
2024
Anticuerpos anti-pd-1 y composiciones
G Galler, M Gad, K Koefoed, ID Horak, T Bouquin, M Kragh, M Pedersen
ES Patent App. 16,774,691 T, 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–20